Placental Alkaline Fosfatase Antilichaam / ALPP / PLAP

Reacts with a 70kDa membrane-bound isozyme (Regan and Nagao type) of Placental Alkaline Phosphatase (PLAP) occurring in the placenta during the 3rd trimester of gestation. It is highly specific for PLAP and shows no cross-reaction with other isozymes of alkaline phosphatase. Anti-PLAP reacts with germ cell tumors and can discriminate between these and other neoplasms. Somatic neoplasms e.g. breast, gastrointestinal, prostatic, and urinary cancers may also immunoreact with antibodies to PLAP. Anti-PLAP positivity in conjunction with anti-keratin negativity favors seminoma over carcinoma. Germ cell tumors are usually anti-keratin positive, but they regularly fail to stain with anti-EMA, whereas most carcinomas stain with anti-EMA. Anti-PLAP has been useful in the diagnosis of gestational trophoblastic disease.

Flow cytometry: 1-2ug/million cells, Immunofluorescence: 1-3 µg/mL, Immunohistochemistry (FFPE) : 1-2 µg/mL for 30 min at RT, Western blot: 2-4 µg/mL

P05187

Human

Purified human PLAP protein was used as the immunogen for the Placental Alkaline Phosphatase antibody.

PL8-F6

FACS, IF, IHC-P, WB

Protein G affinity chromatography

Purified

This Placental Alkaline Phosphatase antibody is available for research use only.

Store the Placental Alkaline Phosphatase antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide) .

0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05% sodium azide

Optimal dilution of the Placental Alkaline Phosphatase antibody should be determined by the researcher.

Cytoplasmic and cell surface

Western blot testing of human JEG-3 cell lysate with Placental Alkaline Phosphatase antibody (clone PL8-F6) . Predicted molecular weight ~58 kDa but routinely visualized at 60-70 kDa.